A Conversation With California’s New Attorney General
By Jill Cowan,
New York Times
| 04. 28. 2021
On Friday, the former state lawmaker Rob Bonta officially became California’s attorney general, stepping into a role that has served as a launching pad for some of the state’s most powerful politicians.
Mr. Bonta was the last of three high-profile appointments by Gov. Gavin Newsom in what observers have described as the most significant reshuffling of Democratic power the state has experienced in years. That Mr. Newsom now has close allies in three of the state’s top posts is likely to pay dividends as he campaigns to keep his job in a recall election later this year.
But political calculus aside, the attorney general wields broad power to shape the state’s criminal justice agenda — a task that has taken on heightened urgency amid a reckoning over racism and police violence.
During his second full day on the job, I spoke with Mr. Bonta about his priorities. Our conversation has been edited and condensed.
Yesterday your office announced that you would release more gun violence data to researchers and the public. What else is on the agenda in the...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
